SAB Biotherapeutics Statistics
Total Valuation
SABS has a market cap or net worth of $26.40 million. The enterprise value is -$12.21 million.
| Market Cap | 26.40M |
| Enterprise Value | -12.21M |
Important Dates
The next estimated earnings date is Monday, August 19, 2024, before market open.
| Earnings Date | Aug 19, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
SABS has 9.23 million shares outstanding. The number of shares has increased by 83.38% in one year.
| Shares Outstanding | 9.23M |
| Shares Change (YoY) | +83.38% |
| Shares Change (QoQ) | +67.38% |
| Owned by Insiders (%) | 19.15% |
| Owned by Institutions (%) | 36.91% |
| Float | 5.84M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 10.14 |
| Forward PS | n/a |
| PB Ratio | 0.50 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.65, with a Debt / Equity ratio of 0.10.
| Current Ratio | 5.65 |
| Quick Ratio | n/a |
| Debt / Equity | 0.10 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -132.21 |
Financial Efficiency
Return on equity (ROE) is -109.90% and return on invested capital (ROIC) is -72.18%.
| Return on Equity (ROE) | -109.90% |
| Return on Assets (ROA) | -72.80% |
| Return on Capital (ROIC) | -72.18% |
| Revenue Per Employee | $45,657 |
| Profits Per Employee | -$699,398 |
| Employee Count | 57 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -65.54% in the last 52 weeks. The beta is 0.64, so SABS's price volatility has been lower than the market average.
| Beta (5Y) | 0.64 |
| 52-Week Price Change | -65.54% |
| 50-Day Moving Average | 3.39 |
| 200-Day Moving Average | 5.82 |
| Relative Strength Index (RSI) | 43.75 |
| Average Volume (20 Days) | 14,497 |
Short Selling Information
The latest short interest is 34,186, so 0.37% of the outstanding shares have been sold short.
| Short Interest | 34,186 |
| Short Previous Month | 33,924 |
| Short % of Shares Out | 0.37% |
| Short % of Float | 0.59% |
| Short Ratio (days to cover) | 1.04 |
Income Statement
In the last 12 months, SABS had revenue of $2.60 million and -$39.87 million in losses. Loss per share was -$6.78.
| Revenue | 2.60M |
| Gross Profit | 2.60M |
| Operating Income | -42.06M |
| Pretax Income | -39.87M |
| Net Income | -39.87M |
| EBITDA | -34.76M |
| EBIT | -39.57M |
| Loss Per Share | -$6.78 |
Balance Sheet
The company has $44.06 million in cash and $5.45 million in debt, giving a net cash position of $38.61 million or $4.18 per share.
| Cash & Cash Equivalents | 44.06M |
| Total Debt | 5.45M |
| Net Cash | 38.61M |
| Net Cash Per Share | $4.18 |
| Equity (Book Value) | 52.82M |
| Book Value Per Share | 5.72 |
| Working Capital | 38.65M |
Cash Flow
In the last 12 months, operating cash flow was -$34.26 million and capital expenditures -$260,478, giving a free cash flow of -$34.52 million.
| Operating Cash Flow | -34.26M |
| Capital Expenditures | -260,478 |
| Free Cash Flow | -34.52M |
| FCF Per Share | -$3.74 |
Margins
Gross margin is 100.00%, with operating and profit margins of -1,616.31% and -1,531.84%.
| Gross Margin | 100.00% |
| Operating Margin | -1,616.31% |
| Pretax Margin | -1,531.84% |
| Profit Margin | -1,531.84% |
| EBITDA Margin | -1,335.64% |
| EBIT Margin | -1,520.34% |
| FCF Margin | -1,326.60% |
Dividends & Yields
SABS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -83.38% |
| Shareholder Yield | -83.38% |
| Earnings Yield | -151.03% |
| FCF Yield | -130.79% |
Analyst Forecast
The average price target for SABS is $13.00, which is 354.55% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $13.00 |
| Price Target Difference | 354.55% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 4 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on January 5, 2024. It was a reverse split with a ratio of 1:10.
| Last Split Date | Jan 5, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:10 |
Scores
SABS has an Altman Z-Score of -2.15 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.15 |
| Piotroski F-Score | 3 |